Seres Therapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, MCRB, Seres Therapeutics Inc, priceseries

Seres Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
6.31
Close
6.59
High
6.60
Low
6.26
Previous Close
6.30
Daily Price Gain
0.29
YTD High
9.00
YTD High Date
Jan 4, 2022
YTD Low
6.22
YTD Low Date
Mar 4, 2022
YTD Price Change
-2.25
YTD Gain
-25.45%
52 Week High
25.05
52 Week High Date
Jun 30, 2021
52 Week Low
5.41
52 Week Low Date
Sep 14, 2021
52 Week Price Change
-11.16
52 Week Gain
-62.87%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 16. 2017
10.49
Jun 30. 2017
11.47
10 Trading Days
9.37%
Link
LONG
Jul 14. 2017
11.26
Aug 1. 2017
13.12
12 Trading Days
16.54%
Link
LONG
Sep 14. 2017
14.34
Sep 29. 2017
16.15
11 Trading Days
12.63%
Link
LONG
Oct 30. 2018
6.69
Nov 19. 2018
8.03
14 Trading Days
20.08%
Link
LONG
Jan 3. 2019
5.13
Jan 17. 2019
5.68
10 Trading Days
10.68%
Link
LONG
Aug 8. 2019
2.63
Aug 29. 2019
3.50
15 Trading Days
33.21%
Link
LONG
Oct 29. 2019
3.46
Nov 11. 2019
3.66
9 Trading Days
5.84%
Link
LONG
May 6. 2020
3.80
May 14. 2020
4.43
6 Trading Days
16.48%
Link
LONG
May 15. 2020
4.60
Jun 1. 2020
5.16
10 Trading Days
12.15%
Link
LONG
Aug 4. 2020
4.20
Sep 3. 2020
24.78
22 Trading Days
489.97%
Link
LONG
Oct 2. 2020
27.69
Oct 20. 2020
32.00
12 Trading Days
15.58%
Link
LONG
Nov 3. 2020
30.35
Nov 19. 2020
33.30
12 Trading Days
9.72%
Link
LONG
Mar 31. 2021
20.59
Apr 1. 2021
21.63
1 Trading Days
5.05%
Link
LONG
Jun 17. 2021
20.90
Jul 1. 2021
22.53
10 Trading Days
7.82%
Link
LONG
Sep 15. 2021
6.35
Sep 29. 2021
6.86
10 Trading Days
8.08%
Link
LONG
Nov 1. 2021
6.44
Nov 29. 2021
8.91
19 Trading Days
38.28%
Link
Company Information
Stock Symbol
MCRB
Exchange
NasdaqGS
Company URL
http://www.serestherapeutics.com
Company Phone
617 945 9626
CEO
Roger J. Pomerantz
Headquarters
Massachusetts
Business Address
200 SIDNEY STREET, CAMBRIDGE, MA 02139
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001609809
About

Seres Therapeutics, Inc. is a microbiome therapeutics platform company, which engages in developing biological drugs. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. The company was founded by Geoffrey von Maltzahn, David A. Berry and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Description

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection (CDI). The company also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI. Its product candidates in pre-clinical development comprise SER-301, a synthetic Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease; and SER-155, an Ecobiotic microbiome therapeutic for the prevention of transplant-related mortality. Seres Therapeutics, Inc. has a strategic collaboration with Nestle Health Science and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading